Case report

Helicobacter pylori infection manifesting as Hypereosinophilic syndrome and immune thrombocytopenia complicated by portal vein thrombosis and ischemic colitis

Awni Alshurafa *, Mustafa Sied, Maab Elkhdier, Ahmed M. Abdalhadi, Mohamed A. Yassin

Hamad Medical Corporation, Doha, Qatar

**Article Info**

Article history:
Received 18 August 2021
Received in revised form 7 February 2022
Accepted 11 February 2022

Keywords:
Hypereosinophilic syndrome
Immune thrombocytopenia
H. Pylori
Portal vein thrombosis

**Abstract**

Hypereosinophilic syndromes (HES) are a group of uncommon disorders characterized by persistent eosinophil overproduction which can lead to tissue damage and organs dysfunction secondary to eosinophils tissue infiltration and inflammatory mediators' release. Causes of secondary HES include parasitic infection, some solid tumors, underlying connective tissue disease, allergic conditions and T cell lymphoma. *Helicobacter pylori* (H. pylori) has been reported only once as a cause of secondary HES in the literature. We report the second case of *H. pylori* infection in a 29-year-old male patient who presents with HES and secondary Immune thrombocytopenic purpura (ITP). This case is different from the first reported case by the presence of HES complication on presentation manifesting as portal vein thrombosis, which was further complicated by ischemic colitis. *H. pylori* eradication therapy alone was successful in a resolution of hypereosinophilia and platelets recovery without the need of corticosteroids or any other treatment.

**Introduction**

Hypereosinophilia (HE) is defined as an absolute eosinophil count (AEC) > 1.5 × 10⁹/L on two tests at least four weeks apart and/or evidence of tissue hypereosinophilia confirmed by pathologic examination. Hypereosinophilic syndrome (HES) is hypereosinophilia and organ dysfunction, which is related to tissue HE, given that other causes of organ damage has been excluded [1]. HES can be categorized as primary (clonal), secondary (reactive), or idiopathic. Causes of secondary HES include parasitic infection, some solid tumors, underlying connective tissue disease, allergic conditions, and T cell lymphoma [2,3]. *Helicobacter pylori* (H. pylori) has been reported only once in the literature as a cause of secondary HES [4]. Immune thrombocytopenia (ITP) is an acquired immune mediated process characterized by transient or persistent thrombocytopenia [5]. ITP is a common bleeding disorder with reported incidence of 3.9 per 100,000 [6]. ITP is subclassified into primary and secondary. Secondary causes include autoimmune diseases, immunodeficiency syndromes, lymphoid malignancies, and underlying infection. In contrast to HES, *H. pylori* is well reported as a secondary cause of ITP and it’s eradication results in platelets counts recovery [7-9]. Thromboembolism estimated to affect around 25% of HES patients, causing 5-10% mortality, and it can be the presenting complaint [10-12]. We report a case of a 29-year-old male patient who presented with abdominal pain and bloody diarrhea and was found to have *H. pylori*-related HES and secondary ITP complicated by portal vein thrombosis and ischemic colitis. *H. pylori* eradication alone results in platelets count recovery and eosinophils normalization without the need for any further treatment.

**Case report**

A 29-year-old Bangladeshi male patient, previously healthy, presented to the Emergency Department complaining of generalized abdominal pain and bloody diarrhea for 10 days. He denied nausea, vomiting, fever, skin rash, anorexia, or weight loss. He is not known to have any chronic gastrointestinal disease or previous parasitic infection. Also, He denied any new drug intake or any allergic reaction. Family history is not significant for malignancy.

On General examination, the patient was vitally stable, with no documented fever, skin rash, or palpable lymphadenopathy. The abdominal examination showed generalized tenderness, no organomegaly, and normal bowel sounds. Other systems examination was unremarkable.

Complete blood counts showed Hemoglobin of 14.7 gm/dL (13.5–17.5 gm/dL), leukocytes of 23,500/L (4000–10,000/L) with
absolute eosinophil count of 14,700/L (0–500/L), and platelets counts of 42,000/L (150,000–400,000/L).

Renal, liver function tests, lactate, and coagulation profile were in normal limits. Stool tested twice negative for ova and parasites. Peripheral smear reported twice as marked eosinophilia, mild lymphocytosis, and moderate thrombocytopenia, no blasts or atypical cells were seen. Chest X ray and echocardiography were unremarkable.

CT abdomen revealed portal vein thrombosis with diffuse concentric thickening of colonic segments involving hepatic flexure, transverse colon, splenic flexure up to the lower part of the descending colon reported as inflammatory versus ischemic colitis. The liver and spleen showed normal echotexture and size, and there was no lymphadenopathy.

The patient was admitted under the medical team for further evaluation and management. Based on his age, clinical presentation, and imaging, the initial impression was inflammatory bowel disease complicated by portal vein thrombosis, and he was started on IV hydration and anticoagulation.

The gastroenterology team was consulted; they recommended colonoscopy, it was done and showed a picture of ischemic colitis reported as sharply defined edematous segmental erythema at the proximal transverse colon to the splenic flexure, and no gangrene was found (Fig. 1). A biopsy was taken from the transverse colon. The histopathological examination showed fragments of colonic mucosa with focal surface mucosa denudation, focal ulceration, and numerous eosinophils in the lamina propria.

In view of colonoscopy findings and severe eosinophilia, the hematology team was consulted to exclude underlying myeloproliferative disorder. Patient was tested negative for FIP1L1–PDGFRA (FIP1-like 1 platelet-derived growth factor receptor A), PDGFRB (Platelet Derived Growth Factor Receptor Beta), JAK2V617F, CALR, and BCR-ABL mutations.

Also, he was investigated to rule out underlying thrombophilia. Factor V Leiden, prothrombin gene mutation, antinuclear antibody (ANA), antcardiolipin, lupus anticoagulant, and Beta-2 glycoprotein antibody tests came negative.

He was also evaluated for the other secondary causes of ITP. Hepatitis B, hepatitis C, HIV, and ANA results were negative. But H. pylori stool antigen came positive which was sent as part of thrombocytopenia work up.

The patient was started on H. pylori quadruple eradication regimen including Bismuth subcitrate, Tetracycline, Metronidazole, and proton pump inhibitor (PPI) for 14 days.

There was significant improvement in eosinophilia and thrombocytopenia after starting H. pylori treatment (see Fig. 2). Eosinophils dropped to $10.9 \times 10^9$/L from $15.8 \times 10^9$/L, and platelets increased to $95 \times 10^9$/L from $40 \times 10^9$/L after one week of treatment. Follow up CBC after two weeks showed eosinophils of $0.1 \times 10^9$/L and platelets of $131 \times 10^9$/L and patient was tolerating and complaint to anticoagulation. Given this dramatic improvement on H. pylori eradication, we concluded that the final diagnosis is H. pylori-related HES, secondary ITP, portal vein thrombosis complicated by ischemic colitis was made.

The most challenging part in this patient’s management was the concomitant occurrence of portal vein thrombosis and ischemic colitis, which necessitate starting anticoagulation on one hand and thrombocytopenia which put him at high risk of bleeding on the other hand. Balancing the benefits and risks, we decided to keep the patient on prophylactic anticoagulation and when the platelets increased to more than 50,000/L, he was started on full anticoagulation.

Discussion

Hypereosinophilic syndromes (HES) are a group of uncommon disorders characterized by persistent eosinophils overproduction which can lead to tissue damage and organs dysfunction secondary to eosinophils tissue infiltration and inflammatory mediators release [1]. Although HES can affect any organ in the body, the most commonly involved organs are the skin, lungs, heart, and gastrointestinal tract [13]. HES can be classified as primary (clonal), secondary (reactive), or idiopathic [2].

Clonal HES occurs in the setting of an underlying stem cell, eosinophilic, or myeloid neoplasm [2]. To diagnose clonal eosinophilia needs to demonstrate either a molecular/cytogenetic marker of clonality or bone marrow examination that is consistent with an otherwise classified myeloid malignancy [14]. Our patient had severe eosinophilia, thrombocytopenia, and thrombosis so we evaluated him for underlying primary HES by sending the FIP1L1–PDGFRA fusion gene, PDGFRB JAK2V617F mutation, CALR, and BCR-ABL mutation. All tests came negative, and because of significant response to H. pylori eradication, we were able to rule out primary HES.

Infections cause hypereosinophilia by triggering Th2 cell-derived IL-5, IL-3, and GM-CSF. Eosinophils enhance immune responses by releasing cytokines and chemokines. While eosinophil mediated tissue inflammatory response by different mechanisms, it is involved in various microbial, such as viruses and parasites, antigens process and presentation [15–17].

H. pylori is a gram-negative bacterium that colonizes the gastric mucosa. It has been implicated in the development of peptic ulcer disease, gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, unexplained iron deficiency anemia, and immune thrombocytopenia but it was only reported once as cause of secondary HES [4,7]. Mangal et al. report the first case of H. pylori presenting with HES and secondary ITP in a 66-year-old male patient who presented with abdominal pain and symptomatic ITP, work up showed positive urea breath test and eosinophilic duodenitis. Anti-Helicobacter pylori treatment alone results in clinical and hematological improvement.

The exact mechanism of H. pylori-induced ITP is still uncertain. However, there are different hypotheses. One of these hypotheses is molecular mimicry which means that our bodies produce antibodies in response to H. pylori infection leads to cross-reactivity with platelet surface antigens. Chronic H. pylori infection stimulates the immune system to produce non-specific autoantibodies. However, this does not explain autoimmune response in ITP patients. Also, it has been reported that H. pylori-infected patients have enhanced phagocytic capacity and low expression levels of inhibitory FcγRIIB in their circulating monocytes. Activation of dendritic cells and macrophages by H. pylori released components found to be responsible as well. Moreover, H. pylori can induce platelets aggregation by direct interaction of IgG antibodies and von Willebrand

Fig. 1. colonoscopy shows sharply defined edematous segmental erythema at proximal transverse colon to splenic flexure suggestive of ischemic colitis.
factor against with their compatible receptors, FcyRIIA and GPIb, on platelets [18].

In our patient, the presentation was different and more challenging as he presented with abdominal pain and bloody diarrhea and initial workup showed severe eosinophilia, thrombocytopenia, portal vein thrombosis, and picture of ischemic vs inflammatory colitis. The differential diagnosis at that point was infectious (especially parasitic), inflammatory colitis, thrombophilia or myeloproliferative disorder. *H. pylori* stool antigen was sent as part of ITP work up. However, when the patient showed improvement by a dramatic decrease in eosinophils and improvement in the platelets with *H. pylori* treatment, the final diagnosis was *H. pylori*-related HES and ITP.

Not only the diagnosis was challenging in this patient but also the management wasn’t straightforward. The presence of portal vein thrombosis and ischemic colitis indicate the use of anticoagulation to prevent further thrombosis progression and gangrene formation, but the high risk of bleeding secondary to thrombocytopenia was a concern.

Balancing the benefits and risks, we decided to keep the patient on prophylactic anticoagulation and when the platelets increased to more than 50,000/L, he was started on full anticoagulation.

**Conclusion,**

we report the second case of *H. pylori* presenting with HES and secondary ITP. This case was different from the first reported case by the presence of HES complication on presentation manifesting as portal vein thrombosis which was further complicated by ischemic colitis. *H. pylori* eradication therapy alone was successful in resolution of hypereosinophilia and platelets recovery without the need of corticosteroids or any other treatment.

**Declaration**

On behalf of all authors, the corresponding author states that there is no conflict of interest.

**References**

[1] Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130(3):607–12. https://doi.org/10.1016/j.jaci.2012.02.019

[2] Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133(5):468–92. https://doi.org/10.1111/j.1365-2141.2006.06038.x

[3] Nair AP, Soliman A, Al Masalamani MA, et al. Clinical outcome of eosinophilia in patients with COVID-19: a controlled study. Acta Bio-Med Atenei Parm 2020;91(4):e20200164.https://doi.org/10.23750/abm.v91i4.10564

[4] Mangal. Helicobacter pylori infection presenting as a hypereosinophilic syndrome and secondary immune thrombocytopenia. Accessed June 22, 2021. [https://www.jahospitaljournal.com/article/issue/1638-5127/year=2020/volume=1;issue=1;spage=141.epage=144;article=Mangal](https://www.jahospitaljournal.com/article/issue/1638-5127/year=2020/volume=1;issue=1;spage=141.epage=144;article=Mangal)

[5] Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenia purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93. https://doi.org/10.1182/blood-2008-07-162503

[6] Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitran-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83(2):83–9. https://doi.org/10.1111/j.1365-2141.2009.07124.x

[7] Stasi R, Sarpattwari A, Segel JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenia purpura: a systematic review. Blood 2009;113(6):1231–40. https://doi.org/10.1182/blood-2008-07-167155

[8] Barbosa AM de C, Ribeiro RA, Silva CSM, et al. Platelet count response to Helicobacter pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. Hematol Transfus Cell Ther 2018;40(1):12–7. https://doi.org/10.1007/jhj.2017.09.005

[9] Mohamed MFH, Al-Shokri SD, Shunnar KM, et al. Prevalence of venous thromboembolism in critically ill COVID-19 patients: systematic review and meta-analysis. Front Cardiovasc Med 2021;7:598846.https://doi.org/10.3389/fcvm.2020.598846

[10] Ogbugu PU, Rosing DR, Horne MK. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27(3):457–75. https://doi.org/10.1016/j.iac.2007.01.001

[11] Liu Y, Meng X, Feng J, Zhou X, Zhu H. Hypereosinophilia with concurrent venous thromboembolism: clinical features, potential risk factors, and short-term outcomes in a Chinese cohort. Sci Rep 2020;10(1):8359. https://doi.org/10.1038/s41598-020-60128-4

[12] Wallace KL, Elias MK, Butterfield JH, Weiler CR. Hypereosinophilic syndrome and thrombosis: a retrospective review. J Allergy Clin Immunol 2013;132(1):A182. https://doi.org/10.1016/j.jaci.2012.12.1059

[13] Roufosse FE, Goldman M, Cojoc E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007;2:37. https://doi.org/10.1186/1750-1172-2-37

[14] Current Concepts on the pathogenesis of the hypereosinophilic syndrome/ chronic eosinophilic leukemia. Accessed June 24, 2021. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642145/)

[15] Shin MH, Lee YA, Min DY. Eosinophil-mediated tissue inflammatory responses in helminth infection. Korean J Parasitol 2009;47(Suppl):S125–31. https://doi.org/10.3347/kjp.2009.47.S3.S125

[16] Iqbal F, Soliman A, De Sanctis V, et al. Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study. Acta Bio-Med Atenei Parm 2020;91(4):e20200164.https://doi.org/10.23750/abm.v91i4.10564

[17] Soliman AT, Prabhakaran Nair A, Al Masalamani MS, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus non-diabetic symptomatic patients with COVID-19: a comparative study. Acta Bio-Med Atenei Parm 2020;91(3):e20200101.https://doi.org/10.23750/abm.v91i3.10231

[18] Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol 2014;20(3):714–23. https://doi.org/10.3748/wjg.v20.i3.714